Leadiant Biosciences is managed by a team of executives with exceptional experience in the all different aspects of the pharmaceutical business, with special expertise in the development, registration and commercialization of rare disease products.
Dr. Brughera is Group Chief Executive Officer at Leadiant Biosciences S.p.A.
Dr. Brughera has extensive experience in drug development, portfolio optimization, business development and general management particularly in the oncology and rare disease areas across several global pharmaceutical and biotech companies.
He drove the commercial revival of a lead oncology product line resulting in its successful sale to Baxalta and out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. He has extensive track record of discovery, development and registration of products in Oncology and Rare Disease.
He has held several positions for the Sigma-Tau Group, including Corporate R&D Managing Director.
Marco previously served as Vice President of Preclinical Development at Nerviano Medical Sciences (NMS, and Managing Director at Accellera, an independent CRO with the NMS Group.
He initially held several senior level positions in the areas of research and development with Pharmacia, Pfizer and Farmitalia Carlo Erba.
Dr. Brughera earned his degree in Veterinary Medicine from the University of Milano. He attended Management Courses at Thunderbird American Graduate Business School at Arizona State University and MIT. He was EFPIA deputy topic leader for the ICH review of the Oncology Therapeutic Guidance, publication record includes more 60 publications/communications.
He is currently Board Member of Fennec Pharmaceuticals Inc, Exelead Inc. and Naicons. He was previously Board Member at Gentium, Soligenix and Lee’s Pharmaceutical.
Ms. Capuano is the Chief Financial Officer of Leadiant Biosciences S.p.A. where she is responsible for the overall management of finance, administration, control and planning, as well as responsible for supervising and supporting the group companies in financial and business matter. Ms Capuano has developed her strong expertise in finance and accounting across her professional career in the auditing of several global companies, mainly in the chemical and pharmaceutical industries. She has an extensive experience in the audit of financial statements prepared in accordance with Italian (ITA GAAP), international (IAS / IFRS) and US accounting principles (US GAAP), analysis and accounting support for financial transactions (acquisition, mergers, demergers, sales of companies and branches), development and implementation of organisation models under the provisions of Legislative Decree n. 231 of 2001, of financial and accounting process also for compliance with the law n. 262 of 2005, of budgeting, reporting process and strategic plan . Analysis of the internal control system and risk assessment for Sarbanes-Oxley Act compliance. Project manager in GAP analysis, acquisition and vendor due diligences and company listing processes.
Prior to joining the Group, Ms Capuano was an audit senior manager at Ernst & Young Spa, executive in charge of the main listed (and not) Italian and international groups.
Ms Capuano earned her degree in Economics from the University “LUISS” in Rome and she is registered as Chartered Accountant and Statutory Auditor.
Training facilitator and teacher in courses and seminars at professional associations and universities.
Lorenza Laureti is General Counsel of Leadiant Biosciences S.p.A.
She is responsible for the overall management of legal and intellectual property assets including drafting and negotiating scientific and commercial agreements, licensing in and out, business acquisitions and joint ventures, antitrust and trade regulation, commercial dispute resolution, corporate governance as well as related matters.
She joined the Group in 1998 as a business development associate prior to setting up the corporate legal department. She has since held various roles with increasing responsibility and has developed a significant experience and knowledge in legal, IPR’s and compliance matters from a corporate and international point of view, also supporting and managing several M&A operations. She moved to New York City in 2005 with her husband and worked as Director of Legal Affairs of the US subsidiary of the Group, now Leadiant Biosciences, Inc.
Lorenza was Board member of Sigma-Tau Industrie Farmaceutiche Riunite SpA, Biofutura Pharma SpA as well as other national and foreign companies of the ex Sigma-Tau Group. She has been Board member of Exelead Inc. until 2018 and she is currently Board member of Leadiant Biosciences, Inc. and of GP Pharm SA.
She worked in private practice with various law firms specialized in corporate and civil law. She earned her doctorate degree in Law from the University La Sapienza of Rome, Italy and completed her professional education through various courses both in the EU and abroad.
Dr. Noseda is the Chief Scientific Officer (CSO) of Leadiant Biosciences S.p.A.
He is responsible for coordinating and managing the scientific and development programs at a global level as well as to evaluate new opportunities for the Leadiant Group.
After graduating as Medical Doctor in 1984 at the University of Milan and following a Post Doctorate at Bowman Gray School of Medicine (USA), he joined the pharma industry in 1988. He held different managerial positions within the R&D and Marketing organizations of multinational Companies, where he has acquired a significant experience in R&D and strategic/business operations.
He joined sigma-tau in 1998 as Director of Scientific Office and Strategic Alliances within the Corporate R&D organization. In this position he managed key R&D projects and contributed to the finalization of important partnerships (e.g. with Novartis, Debiopharm etc) and to the advancement of product development (from research to product registration).
He has also been Chief Executive Officer of Leadiant Biosciences SA (formerly sigma-tau Research Switzerland) from 2007 to 2017, Under his management this Company developed and advanced a proprietary technology and obtained the Orphan Drug Designation and registration of new products.
He is Board member of RegeneRx Inc, while he was previously Board member of some private Companies as Thule Therapeutics SA, Metheresis Translational Research SA, and Rostaquo srl.
He worked in several therapeutic (and diagnostic) areas, but mostly in high unmet medical need specialty areas as cancer, immune-oncology and rare diseases.
